Prospective, 6 Month, Open Label, Conversion Study From Mycophenolate Mofetil (MMF) to PRMYFORTIC*
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Treatment with MMF often results in adverse GI events, which can lead to dose reductions of MMF and decreased graft function. Enteric-coated mycophenolate sodium (MYFORTIC*) was developed as an alternative formulation of MPA to improve upper GI tract side effects. An improvement in the severity of GI side effects could result in an increased tolerance to MPA and an improvement in patient quality of life. This study will use the GSRS to evaluate improvement in gastrointestinal symptoms.
Condition or disease
Late Complication From Kidney Transplant
This study will evaluate the change in the total gastrointestinal symptom rating scale (GSRS) score at baseline versus month 1,at baseline versus month 3 and at baseline versus month 6 after conversion from MMF to PRMYFORTIC* .
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
renal transplant patients who have received a transplant at least 3 months and experiencing Gastrointestinal symptoms
Received a kidney transplant at least six months
stable graft function (no increased creatinine > 20% in the previous 4 weeks)
Receiving immunosuppressive regimen with stable dose of MMF for at least 4 weeks
Immunosuppressive regimen with a dose of MMF (dose≤ 2.0 g/day) at least 4 weeks OR C0 MMF < 1.4 µg/ml at visit 1 OR patients receiving MMF who have GI side effects
Willing to provide written informed consent
Women of childbearing age must have a negative pregnancy test and use a medically acceptable method of contraception throughout the treatment period;
Over 18 years of age.
GI symptoms assumed or known not to be caused by MPA therapy;
Acute rejection episode ≤ 4 weeks prior to study enrollment;
Liver disease interfering with enterohepatic recirculation, such as active hepatitis B, active hepatitis C, autoimmune hepatitis and liver cirrhosis;
Female patients who are pregnant, lactating or of child bearing potential and not practicing an approved method of birth control;
Active bacterial, viral or fungal infection;
Presence of psychiatric illness that in the view of the investigator would interfere with study requirements;
Known sensitivity to the study drug;
Receiving any investigational drug or have received any investigational drug within 30 days prior to study enrollment.